Evidence map›Paper›PMID 31701351›Full record

ReviewCerebellum (London, England)2020

Speech and Language Disorders in Friedreich Ataxia: Highlights on Phenomenology, Assessment, and Therapy.

Tommaso Schirinzi, Andrea Sancesario, Enrico Bertini, Enrico Castelli, Gessica Vasco

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cerebellum (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Sensitive Quantification of Cerebellar Speech Abnormalities Using Deep Learning Models.IEEE access : practical innovations, open solutions · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tommaso SchirinziDepartment of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. t.schirinzi@yahoo.com.ORCID http://orcid.org/0000-0002-2517-6278
Andrea SancesarioDepartment of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Enrico BertiniDepartment of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Enrico CastelliDepartment of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Gessica VascoDepartment of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Bambino Gesù Children's Hospital · ITUniversity of Rome Tor Vergata · IT

Funding

Ministero della Salute (IT) NET-2013-02356160
6 · The paper itself

Abstract

Speech and language disorders are prominent signs in Friedreich ataxia (FRDA), which significantly impact on patients' quality of life. Despite such relevance, several issues regarding phenomenology, assessment, and treatment are still unmet. In this short review, we thus analyzed the existing literature to summarize what is known about the features of speech and language disorders in FRDA, which methods are used for evaluation and rating, and what are the available therapeutic strategies and future direction of scientific research in this field, in order to highlight critical aspects for a better clinical approach to the problem. FRDA patients often present dysarthria, resulting from central and peripheral causes and additional primary language disorders. Speech disturbances have peculiar characteristics, although variable among patients, and progress along the disease course. Assessment relies on multiple but not specific clinical scales, some of which can also reflect the general severity of ataxia; classical instrumental investigations and novel technologies allow more accurate measurements of several speech parameters, which could found application as potential disease's biomarkers. No successful treatments exist for communication disorders of FRDA patients; however, the tailored speech training or the non-invasive neuromodulation appear as the most reliable therapeutic options to be validate in future trials.

Indexed as

Friedreich AtaxiaHumansLanguage DisordersSpeech DisordersTreatment OutcomeBiomarkersFriedreich ataxiaLanguageSpeechVoice

Identifiers

PMID31701351
OpenAlexW2986453353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.